simtriyo®
centanafadine CIII
capsules 140 mg / 210 mg / 280 mg

The first FDA-approved ADHD treatment of its kind



Designed to treat a wide range of ADHD symptoms for adults, teens, and kids aged 6+ weighing at least 44 lbs (20 kg)

Simtriyo.com

Actor portrayal

Simtriyo is not recommended for children younger than 6 or weighing less than 20 kg due to risk of weight loss.

INDICATION and IMPORTANT SAFETY INFORMATION for SIMTRIYO® (centanafadine) CIII

WARNING: SUICIDAL THOUGHTS AND ACTIONS IN CHILDREN 6 YEARS OF AGE AND OLDER.
Suicidal thoughts and actions can happen in children 6 years of age and older with attention deficit hyperactivity disorder (ADHD), especially within the first few months of treatment. Tell your healthcare provider right away about any changes, especially sudden changes in mood, behavior, thoughts or feelings, or suicidal thoughts or actions.

WARNING: ABUSE, MISUSE, AND ADDICTION
Simtriyo has a chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Simtriyo can lead to overdose and death. This risk is increased with higher doses of Simtriyo or when it is used in ways that are not approved, such as snorting or injection. Your healthcare provider will check you or your child's risk for abuse, misuse, and addiction before starting treatment with Simtriyo and will frequently monitor you or your child throughout treatment. Keep Simtriyo in a safe place and properly dispose of any unused medicine.

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

simtriyo®
centanafadine
capsules 140 mg / 210 mg / 280 mg

Could ADHD be impacting more than you realize?

ADHD is diagnosed based on inattention and hyperactivity/impulsivity. But research shows other lesser-known symptoms are often linked to ADHD.

Classic Diagnostic Symptoms can look like:

- Trouble paying attention
- Interrupting others
- Feeling restless


Lesser-known Associated Symptoms can look like:

- Emotional Dysregulation: big, sudden mood swings, feeling easily overwhelmed when starting tasks
- Executive Dysfunction: problems planning ahead, difficulty starting or finishing projects

The impact?

Many people with ADHD still experience Emotional Dysregulation (45%) and Executive Dysfunction (37%), even with treatment. If unmanaged, all symptoms can take a toll on work, school, relationships, or even self-esteem.

Simtriyo is the first FDA-approved treatment for ADHD designed to target 3 neurotransmitters.



IMPORTANT SAFETY INFORMATION (Cont'd)

Do not take Simtriyo if you or your child:

- are allergic to centanafadine or any of the ingredients in Simtriyo. See the end of this Medication Guide for a complete list of ingredients in Simtriyo.
- are taking, or have stopped taking within the past 14 days, a medicine called a monoamine oxidase inhibitor (MAOI).
- have a condition called pheochromocytoma (a rare tumor that usually grows in the adrenal glands which are above your kidneys).

Simtriyo may cause serious side effects, including:

- **Risks in people with serious heart disease.** Sudden death has happened in people who have heart defects or other serious heart disease. Your healthcare provider should check you or your child carefully for heart problems before starting treatment with Simtriyo. Tell your healthcare provider or go to the nearest emergency room right away if any signs of heart problems develop such as chest pain, shortness of breath, or fainting.

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

simtriyo® centanafadine CII
capsules 140 mg / 210 mg / 280 mg

Simtriyo is designed for a wide range of ADHD symptoms

ADHD can go beyond a lack of focus. It's often a mix of symptoms that's unique to everyone.



Simtriyo was designed to work differently

- Targets 3 neurotransmitters that can play a role in attention, behavior, and mood
- Proven to improve diagnostic symptoms, such as inattention and hyperactivity/impulsivity*
- Studied in a wide range of symptoms related to ADHD

*Based on results from separate Simtriyo studies in adults, teens, and kids.

Common side effects

Simtriyo was studied in kids, teens, and adults with ADHD. These were the most common side effects, occurring in ≥5% of people and at a higher rate than those taking placebo.

Adults
Headache, decreased appetite, insomnia, nausea, dry mouth, diarrhea

Teens (aged 13-17)
Decreased appetite, nausea, rash, headache, abdominal pain

Kids (aged 6-12)
Rash, decreased appetite

These are not all the possible side effects of Simtriyo. Talk to your doctor for more details.



How to take Simtriyo

One capsule, once daily
Simtriyo is taken once daily in the morning—with or without food.

IMPORTANT SAFETY INFORMATION (Cont'd)

- **Increased blood pressure and heart rate.** Your healthcare provider should check you or your child's blood pressure and heart rate before starting treatment, if the dose is increased, and as needed during treatment with Simtriyo.

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

simtriyo® centanafadine (III)
capsules 140 mg / 210 mg / 280 mg

simtriyo GO

Simtriyo GO helps eligible patients get started on treatment—and with ongoing support

FOR ELIGIBLE COMMERCIALLY INSURED PATIENTS

Start now for as little as $20 for a 30-day supply

Savings can be applied while waiting for insurance decision.

Simtriyo GO Savings Card works for both new prescriptions and refills.



Sign up now at **Simtriyo.com/save**
or call **844-3Simtri (844-374-6874)**

Restrictions apply. Eligible patients may pay as little as $20 for a 30-day supply of Simtriyo® with a maximum savings of wholesale acquisition cost plus usual and customary pharmacy charges and an annual maximum savings of 13 uses per calendar year. Benefit cap applies regardless of copay amount.

Eligible patients with commercial insurance that do not have coverage for Simtriyo may pay as little as $20 for up to four (4) 30-day supplies per lifetime. See full Terms and Conditions for more information at Simtriyo.com/savings-support

IMPORTANT SAFETY INFORMATION (Cont'd)

- **Mental problems (psychiatric reactions), including:**
  - worsening behavior or thought problems in people with thought or psychotic disorders
  - manic episodes in people with bipolar disorder
  - new psychotic or manic symptoms in people without bipolar or psychotic disorders

Tell your healthcare provider right away if any mental symptoms or problems develop or worsen during treatment with Simtriyo, including:

- greatly increased energy
- racing thoughts
- unusually grand ideas
- talking more or faster than usual
- severe trouble sleeping
- reckless behavior
- excessive happiness or irritability
- seeing or hearing things that are not real (hallucinations).

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

simtriyo®
centanafadine Ⓒ III
capsules 140 mg / 210 mg / 280 mg



Thinking Simtriyo may be right for you?

If you're still struggling with ADHD, here are a few questions to discuss with your doctor.

- Are my current treatment goals being met?
- Could ADHD still be contributing to challenges at work, school, or in my relationships?
- How does Simtriyo work differently?
- Could Simtriyo help with the ADHD challenges I'm still struggling with?

ADHD symptoms have range. So does Simtriyo.

Learn more about Simtriyo for ADHD symptoms at **Simtriyo.com**

IMPORTANT SAFETY INFORMATION (Cont'd)

- **Allergic reactions, including serious allergic reactions (anaphylaxis).** Serious allergic reactions can happen during treatment with Simtriyo and can lead to hospitalization. Your healthcare provider may stop treatment with Simtriyo if you develop allergic reactions. Tell your healthcare provider right away if you get any signs or symptoms including:
  - raised, red areas on your skin (hives)
  - skin redness or rash, itching, flaking, or peeling
  - dizziness or fainting
  - swelling of face, eyes, lips, throat, or other areas
  - difficulty in breathing or swallowing
- **Slowing of growth (height and weight) in children.** Children should have their height and weight checked often during treatment with Simtriyo. Simtriyo treatment may be stopped if your child is not growing or gaining weight as expected.
- **Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud's phenomenon).** Tell your healthcare provider if any of the following signs and symptoms of circulation problems develop during treatment:
  - fingers or toes feel numb, cool, painful
  - fingers or toes change color from pale, to blue, to red
  - sensitivity to temperature in fingers or toes

Call your healthcare provider right away if any unexplained wounds appear on the fingers or toes during treatment with Simtriyo.

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

simtriyo®
centanafadine CIII
capsules 140 mg / 210 mg / 280 mg

IMPORTANT SAFETY INFORMATION (Cont'd)

- **Serotonin Syndrome.** A potentially life-threatening problem called serotonin syndrome can happen when you take Simtriyo with certain other medicines. Stop taking Simtriyo and tell your healthcare provider or go to the nearest hospital emergency room right away if any of the following signs and symptoms develop during treatment:
  - agitation
  - confusion
  - fast heartbeat
  - dizziness
  - flushing
  - tremors, stiff muscles, or muscle twitching
  - seizures
  - coma
  - changes in blood pressure
  - sweating
  - high body temperature (hyperthermia)
  - loss of coordination
  - nausea, vomiting, diarrhea
  - seeing or hearing things that are not real (hallucinations)
- **New or worsening tics or worsening Tourette's syndrome.** Tell your healthcare provider if any new or worsening tics or worsening Tourette's syndrome symptoms develop during treatment with Simtriyo.
- **Allergic reactions to FD&C Yellow No. 5.** Simtriyo 210 mg capsules contain a yellow food dye called tartrazine (FD&C No. 5) which may cause allergic-type reactions (including bronchial asthma) in certain people. If you are allergic to aspirin, you may be more likely to react to tartrazine. Tell your healthcare provider if any symptoms of allergic reactions develop during treatment, including hives, rash, swelling, or trouble breathing.

Before taking Simtriyo, tell your healthcare provider about all of your medical conditions, including if you or your child:

- have heart problems, heart disease, heart defects, or have a family history of sudden death, or high blood pressure
- have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression
- have circulation problems in fingers and toes
- have or had uncontrolled movements or sounds (tics) or Tourette's syndrome, or have a family history of tics or Tourette's syndrome
- have an allergy or sensitivity to FD&C Yellow No. 5 (tartrazine)
- have liver problems
- are pregnant or plan to become pregnant. It is not known if Simtriyo will harm the unborn baby. Talk to your healthcare provider about the risk to the unborn baby if you or your child take Simtriyo during pregnancy.
  - If you or your child become pregnant during treatment with Simtriyo, talk to your healthcare provider about registering with the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/adhd-medications/.
- are breastfeeding or plan to breastfeed. It is not known if Simtriyo passes into the breast milk. Talk to your healthcare provider about the best way to feed the baby during treatment with Simtriyo.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Simtriyo and certain other medicines may affect each other causing possible serious side effects.

Especially tell your healthcare provider if you or your child take:

- a MAOI, including linezolid or intravenous methylene blue
- medicines used to treat mood, anxiety, psychotic or thought disorders, including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants
- medicines used to treat migraine headaches called triptans
- tramadol, fentanyl, meperidine, methadone, or other opioids
- tryptophan
- St. John's Wort
- other central nervous system (CNS) stimulants including other ADHD medicines

The most common side effects of Simtriyo include:

- **Children Aged:**
  - **6 to 12 Years:** rash, decreased appetite
  - **13 to 17 Years:** decreased appetite, nausea, rash, headache, stomach area (abdominal) pain
- **Adults:** headache, decreased appetite, trouble sleeping (insomnia), nausea, dry mouth, diarrhea

These are not all the possible side effects of Simtriyo. For more information, ask your healthcare provider or pharmacist.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

INDICATION

Simtriyo is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older weighing at least 44 pounds (20 kg).

Simtriyo is not recommended for use in children under 6 years of age or weighing less than 44 pounds (20 kg).

Simtriyo is a federally controlled substance (CIII) because it contains centanafadine, which can be a target for people who abuse prescription medicines or street drugs.

Please see additional Important Safety Information, including BOXED WARNINGS, throughout and FULL PRESCRIBING INFORMATION and MEDICATION GUIDE.

© 2026 Otsuka America Pharmaceutical, Inc.
All rights reserved. September 2026 26US26EBC0045

Otsuka